Keyword: Biohaven Pharmaceuticals
11 would-be blockbusters span several therapeutic areas, including CNS, oncology, hematology, inflammatory diseases and metabolic disorders.
We've assembled a list of the top 10 most-anticipated new drug launches of 2020 based on estimated global sales in 2024. Of those 10, eight could break the blockbuster barrier in four short years—putting a new batch of heavy hitters in pharma's ranks.
It's a new year, which means it's a new opportunity for drugmakers hoping to pass FDA muster for new therapies––some of which have blockbuster hopes.
Biohaven and Allergan are awaiting FDA action on their oral CGRP migraine meds. Biohaven is much smaller, but CEO Coric said his company can compete.
While forthcoming migraine meds from Eli Lilly, Allergan and Biohaven do beat placebo, they're not much better than existing triptan drugs, ICER says.
Biohaven Pharmaceuticals has been unexpectedly hit by a complete response letter for using an Apotex API.
